Aviva PLC decreased its holdings in Albemarle Co. (NYSE:ALB) by 3.8% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 59,942 shares of the specialty chemicals company’s stock after selling 2,350 shares during the period. Aviva PLC owned about 0.06% of Albemarle worth $5,981,000 as of its most recent filing with the Securities & Exchange Commission.
Other large investors have also bought and sold shares of the company. Credit Agricole S A acquired a new position in shares of Albemarle in the second quarter worth $123,000. SeaCrest Wealth Management LLC grew its stake in shares of Albemarle by 145.9% during the second quarter. SeaCrest Wealth Management LLC now owns 1,692 shares of the specialty chemicals company’s stock worth $160,000 after purchasing an additional 1,004 shares in the last quarter. Valeo Financial Advisors LLC grew its stake in shares of Albemarle by 17,210.0% during the third quarter. Valeo Financial Advisors LLC now owns 1,731 shares of the specialty chemicals company’s stock worth $171,000 after purchasing an additional 1,721 shares in the last quarter. Palladium Partners LLC acquired a new position in shares of Albemarle during the third quarter worth $205,000. Finally, Hudson Valley Investment Advisors Inc. ADV acquired a new position in shares of Albemarle during the third quarter worth $215,000. Institutional investors and hedge funds own 92.73% of the company’s stock.
In other news, EVP Karen G. Narwold sold 3,100 shares of the company’s stock in a transaction dated Monday, November 26th. The shares were sold at an average price of $96.54, for a total value of $299,274.00. Following the completion of the sale, the executive vice president now directly owns 27,142 shares of the company’s stock, valued at $2,620,288.68. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. 0.80% of the stock is owned by insiders.
Shares of ALB opened at $88.65 on Friday. Albemarle Co. has a 1-year low of $86.75 and a 1-year high of $138.67. The firm has a market capitalization of $9.90 billion, a P/E ratio of 19.31, a P/E/G ratio of 1.06 and a beta of 1.52. The company has a debt-to-equity ratio of 0.38, a current ratio of 1.83 and a quick ratio of 1.18.
Albemarle (NYSE:ALB) last announced its quarterly earnings results on Wednesday, November 7th. The specialty chemicals company reported $1.31 earnings per share for the quarter, beating analysts’ consensus estimates of $1.25 by $0.06. Albemarle had a net margin of 10.44% and a return on equity of 15.39%. The firm had revenue of $778.00 million during the quarter, compared to analysts’ expectations of $796.79 million. During the same period in the previous year, the company earned $1.08 earnings per share. Albemarle’s quarterly revenue was up 3.0% compared to the same quarter last year. As a group, sell-side analysts predict that Albemarle Co. will post 5.43 earnings per share for the current fiscal year.
The business also recently declared a quarterly dividend, which will be paid on Wednesday, January 2nd. Investors of record on Friday, December 14th will be given a $0.335 dividend. The ex-dividend date is Thursday, December 13th. This represents a $1.34 dividend on an annualized basis and a yield of 1.51%. Albemarle’s dividend payout ratio (DPR) is presently 29.19%.
A number of equities analysts recently commented on ALB shares. ValuEngine downgraded shares of Albemarle from a “hold” rating to a “sell” rating in a research note on Friday, September 28th. Loop Capital set a $130.00 target price on shares of Albemarle and gave the stock a “buy” rating in a research note on Monday, October 8th. SunTrust Banks upgraded shares of Albemarle from a “hold” rating to a “buy” rating and boosted their target price for the stock from $110.00 to $115.00 in a research note on Tuesday, September 4th. Vertical Research started coverage on shares of Albemarle in a research note on Tuesday, September 25th. They set a “sell” rating and a $85.00 target price for the company. Finally, Zacks Investment Research downgraded shares of Albemarle from a “buy” rating to a “hold” rating in a research note on Tuesday, November 20th. Three research analysts have rated the stock with a sell rating, three have assigned a hold rating and seventeen have given a buy rating to the company. The stock presently has an average rating of “Buy” and a consensus price target of $122.43.
TRADEMARK VIOLATION NOTICE: “Aviva PLC Reduces Holdings in Albemarle Co. (ALB)” was originally reported by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are viewing this news story on another site, it was copied illegally and republished in violation of international trademark & copyright laws. The legal version of this news story can be read at https://www.dispatchtribunal.com/2018/12/08/aviva-plc-reduces-holdings-in-albemarle-co-alb.html.
Albemarle Company Profile
Albemarle Corporation develops, manufactures, and markets engineered specialty chemicals worldwide. Its Lithium and Advanced Materials segment offers lithium compounds, including lithium carbonate, lithium hydroxide, lithium chloride, and lithium specialties, as well as reagents, such as butyllithium and lithium aluminum hydride for applications in lithium batteries for consumer electronics and automobiles, high performance greases, thermoplastic elastomers for car tires, rubber soles, plastic bottles, catalysts for chemical reactions, organic synthesis processes, life science, pharmaceutical, and other markets.
Featured Article: What is the Dow Jones Industrial Average (DJIA)?
Want to see what other hedge funds are holding ALB? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Albemarle Co. (NYSE:ALB).
Receive News & Ratings for Albemarle Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Albemarle and related companies with MarketBeat.com's FREE daily email newsletter.